Patents by Inventor Werner Neidhart

Werner Neidhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazines as 11b-HSD1 inhibitors
    Patent number: 7678795
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: March 16, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V Mayweg, Werner Neidhart
  • Pyrazolones as 11b-HSD1 inhibitors for diabetes
    Patent number: 7652057
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: January 26, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V Mayweg, Werner Neidhart
  • TETRAHYDROCINNOLINE DERIVATIVES
    Publication number: 20100016325
    Abstract: Provided herein are compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof, which are useful as pharmaceutical compositions for the treatment of metabolic diseases and disorders.
    Type: Application
    Filed: June 25, 2009
    Publication date: January 21, 2010
    Inventors: Jean Ackermann, Kurt Amrein, Bernd Kuhn, Alexander V. Mayweg, Werner Neidhart
  • Imidazolidinone Derivatives as 11B-HSD1 Inhibitors
    Publication number: 20090275573
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein A and R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: April 16, 2009
    Publication date: November 5, 2009
    Inventors: Jean Ackermann, Kurt Amrein, Bernd Kuhn, Alexander V. Mayweg, Werner Neidhart
  • CB 1 receptor inverse agonists
    Patent number: 7579369
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: August 25, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
    Patent number: 7547697
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: June 16, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Werner Neidhart, Alexander V. Mayweg
  • NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES
    Publication number: 20090149503
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2009
    Publication date: June 11, 2009
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Indazolone derivatives useful as 11b-HSD1 inhibitors
    Patent number: 7528158
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R7 have the significances given in the description and claims can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Jianping Cai, Robert Alan Goodnow, Jr., Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
    Patent number: 7528159
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • 11b-HSD1 inhibitors for the treatment of diabetes
    Patent number: 7507733
    Abstract: Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: March 24, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Pyridines
    Patent number: 7482341
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: January 27, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Benzodioxepine derivatives
    Patent number: 7459480
    Abstract: This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACC? inhibitors.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: December 2, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Luca Claudio Gobbi, Marcel Gubler, Werner Neidhart, Matthias Heinrich Nettekoven
  • NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS
    Publication number: 20080103183
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: October 12, 2007
    Publication date: May 1, 2008
    Inventors: Jean Ackermann, Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart, Tadakatsu Takahashi
  • Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
    Publication number: 20080009499
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 10, 2008
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V. Mayweg, Werner Neidhart
  • CB 1 receptor inverse agonists
    Patent number: 7294644
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: November 13, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Novel CB 1 receptor inverse agonists
    Publication number: 20070238754
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Application
    Filed: May 10, 2007
    Publication date: October 11, 2007
    Inventors: Alexander Mayweg, Hans Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Thiazole derivatives
    Patent number: 7265109
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents have the significance given in the specification, and the compounds are neuropeptide Y(NPY) antagonists which are useful in the treatment of obesity.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: September 4, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Sven Taylor
  • Aminothiazole derivatives
    Patent number: 7253197
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in the specification, and the compounds, salts and esters can be used for the treatment of obesity.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 7, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Guba, Patrizio Mattei, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Thiazole derivatives
    Patent number: 7250431
    Abstract: Thiazole derivatives of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5, a and b have the significance given in the specification. The compounds are neuropeptide Y Y5 receptor antagonists which can be used for the treatment of obesity.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: July 31, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Quinazoline derivatives
    Patent number: 7205309
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Werner Mueller, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger